CD86 and neoplasm: Consequently, SLAMF7 provides an alternative co-stimulatory pathway that may trade speed for functional breadth, an attribute that could be particularly advantageous in tumor or otherwise immunocompromised microenvironments where CD80/CD86 expression is absent or functionally impaired (1).